Diagnostic Value of IP-10 Level in Plasma and Bronchoalveolar Lavage Fluid in Children with Tuberculosis and Other Lung Diseases

Strzelak, Agnieszka; Komorowska-Piotrowska, Anna; Krenke, Katarzyna; Zagórska, Wioletta; Bartosiewicz, W; Feleszko, Wojciech; Kulus, Marek

doi:10.3390/diagnostics12040840

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon gamma inducible protein 10 (IP10) is known as a marker for TB infection and was recently described to be involved as an indicator for sputum culture conversion and treatment monitoring 26 . A combination of IP-10 and RANTES has shown good performance in diagnostic and monitoring in pulmonary TB management 27 – 29 .…”

Section: Introductionmentioning

confidence: 99%

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Ndiaye

Ranaivomanana

Rasoloharimanana

et al. 2022

Sci Rep

View full text Add to dashboard Cite

There is a need for rapid non-sputum-based tests to identify and treat patients infected with Mycobacterium tuberculosis (Mtb). The overall objective of this study was to measure and compare the expression of a selected panel of human plasma proteins in patients with active pulmonary tuberculosis (ATB) throughout anti-TB treatment (from baseline to the end of treatment), in Mtb-infected individuals (TBI) and healthy donors (HD) to identify a putative host-protein signature useful for both TB diagnosis and treatment monitoring. A panel of seven human host proteins CLEC3B, SELL, IGFBP3, IP10, CD14, ECM1 and C1Q were measured in the plasma isolated from an HIV-negative prospective cohort of 37 ATB, 24 TBI and 23 HD. The protein signatures were assessed using a Luminex xMAP® to quantify the plasmatic levels in unstimulated blood of the different clinical group as well as the protein levels at baseline and at three timepoints during the 6-months ATB treatment, to compare the plasma protein levels between culture slow and fast converters that may contribute to monitor the TB treatment outcome. Protein signatures were defined using the CombiROC algorithm and multivariate models. The studied plasma host proteins showed different levels between the clinical groups and during the TB treatment. Six of the plasma proteins (CLEC3B, SELL, IGFBP3, IP10, CD14 and C1Q) showed significant differences in normalised median fluorescence intensities when comparing ATB vs HD or TBI groups while ECM1 revealed a significant difference between fast and slow sputum culture converters after 2 months following treatment (p = 0.006). The expression of a four-host protein markers (CLEC3B-ECM1-IP10-SELL) was significantly different between ATB from HD or TBI groups (respectively, p < 0.05). The expression of the same signature was significantly different between the slow vs the fast sputum culture converters after 2 months of treatment (p < 0.05). The results suggest a promising 4 host-plasma marker signature that would be associated with both TB diagnostic and treatment monitoring.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Ndiaye

Ranaivomanana

Rasoloharimanana

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Ndiaye

Ranaivomanana

Rasoloharimanana

et al. 2022

Preprint

View full text Add to dashboard Cite

Background There is a need for rapid non-sputum-based tests to identify and treat patients infected with Mycobacterium tuberculosis (Mtb). In this study, performance of a human plasma protein signature for both TB triage and treatment monitoring has been evaluated. Methods A panel of seven host proteins CLEC3B, SELL, IGFBP3, IP10, CD14, ECM1 and C1Q were measured in the plasma of a prospective patient cohort undergoing anti-tubercular therapy to distinguish confirmed TB patients from control, to define culture slow and fast converters during an antituberculosis treatment and to monitor the treatment. To validate the protein signatures a Luminex xMAP® assay was used to quantify the proteins in unstimulated plasma isolated from the blood collected from HIV-negative pulmonary TB patients (ATB), at baseline and following 6-months of antituberculosis treatment, latently TB-infected individuals (LTBI) and healthy donors (HD). Protein signatures performances were evaluated using CombiROC algorithm and multivariate models. Findings: We measured the proteins in the plasma of 84 participants including 37 ATB, 24 LTBI and 23 HD. The seven plasma host proteins studied showed different levels between the TB clinical groups and when used separately or in combination, have variable performances for ATB triage and for treatment monitoring. Six of the plasma proteins (CLEC3B, SELL, IGFBP3, IP10, CD14 and C1Q) showed significant differences in normalised median fluorescence intensities when comparing ATB vs HD or LTBI while ECM1 revealed a significant association with early sputum culture conversion after 2 months following treatment (OR 0.004, p = 0.018). For both triage and treatment monitoring, a signature combining 4 host proteins markers (CLEC3B-ECM1-IP10-SELL) was identified, allowing to distinguish ATB from HD or LTBI (respectively, sensitivity = 94%, specificity = 92% and sensitivity = 89%, specificity = 91%) as well as the baseline distinction between slow vs fast sputum culture converters after two months of treatment (AUC = 0.87, sensitivity = 83%, specificity = 84%). Conclusion Our data demonstrate that using a combination of host plasma markers can generate a relevant biosignature for both TB triage and treatment monitoring meeting the WHO Target Product Profile for both purposes.

show abstract

Diagnostic Value of IP-10 Level in Plasma and Bronchoalveolar Lavage Fluid in Children with Tuberculosis and Other Lung Diseases

Cited by 2 publications

References 37 publications

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Contact Info

Product

Resources

About